Targeting cancer’s sweet spot: UGP2 as a therapeutic vulnerability

Sunghoon Kim, Andrew Wolfe, Sung Eun Kim

Research output: Contribution to journalArticlepeer-review


Understanding the mechanisms governing metabolic reprogramming that underlie potential vulnerabilities in cancer cells is key to developing novel therapeutic strategies. The catalytic enzyme UDP-glucose pyrophosphorylase 2 (UGP2) drives the production of UDP-glucose. Our recent work demonstrated the crucial role of UGP2 in cancer growth and its regulation of cellular metabolic processes.

Original languageEnglish
Article number1990676
JournalMolecular and Cellular Oncology
Publication statusAccepted/In press - 2021


  • cancer metabolism
  • glycosylation
  • UDP-glucose
  • UGP2
  • YAP

ASJC Scopus subject areas

  • Molecular Medicine
  • Cancer Research


Dive into the research topics of 'Targeting cancer’s sweet spot: UGP2 as a therapeutic vulnerability'. Together they form a unique fingerprint.

Cite this